10-Q: Medinotec Q2: Strong Revenue Growth Amid Tariff & Control Woes

Medinotec Inc. reported significant revenue growth in Q2 2026, driven by international distribution, but faces challenges from a new U.S. tariff, customer concentration, and ineffective disclosure controls.

Summary

• Consolidated revenue for the three months ended August 31, 2025, increased by 79% to $3,236,305, compared to $1,804,020 in the prior-year period.
• Consolidated revenue for the six months ended August 31, 2025, rose by 76% to $5,370,331, up from $3,055,897 in the corresponding prior-year period.
• Net income for the three months ended August 31, 2025, was $346,566, an increase from $284,749 in the prior year.
• Net income for the six months ended August 31, 2025, was $460,350, up from $371,953 in the prior-year period.
• Gross margin for the three months ended August 31, 2025, expanded to 62% from 46% in the prior-year period, and for the six months, it improved to 55% from 47%.
• Operating expenses surged by 271% for the three months and 191% for the six months, primarily due to increased sales and marketing, R&D, and general and administrative costs.
• The company repaid $939,841 of its related party loan from Minoan Medical Proprietary Limited during the six-month period.
• Cash and cash equivalents decreased to $2,248,095 as of August 31, 2025, from $2,769,686 as of February 28, 2025.
• Disclosure controls and procedures were deemed not effective as of August 31, 2025, with remediation expected by the end of fiscal year 2026.
• A new 30% U.S. tariff on South African imports, effective August 1, 2025, is expected to impact U.S. revenue and gross margins.
• 93% of total revenue for the three and six months ended August 31, 2025, was derived from a single customer, DISA Life Sciences, in South Africa.

Sentiment

Score: 4

Explanation: While revenue and net income showed strong growth, significant concerns arise from the 93% customer concentration, the new 30% U.S. tariff impacting a key market, and the declared ineffectiveness of disclosure controls. The substantial increase in operating expenses and the loss-making U.S. segment also weigh heavily. The debt repayment is positive, but the overall risk profile is elevated.

Positives

• Consolidated revenue increased significantly by 79% for the quarter and 76% for the six months ended August 31, 2025, driven by expansion in the Outside U.S. segment.
• Net income grew to $346,566 for the quarter and $460,350 for the six months ended August 31, 2025, demonstrating improved profitability.
• Gross margin improved to 62% for the quarter and 55% for the six months ended August 31, 2025, indicating better cost management relative to sales.
• The company achieved FDA 510(k) clearance for its OutFlo Aortic Dilatation Balloon Catheter on March 11, 2025, expanding its product portfolio in the North American market.
• Significant repayment of the related party loan by $939,841 during the six-month period ending August 31, 2025, strengthening the balance sheet and reducing leverage.
• The company's 'R&D-light' approach focuses on commercially viable projects and process improvements, optimizing R&D expenditures for higher returns.

Negatives

• U.S. segment revenue decreased by 20% for the three months and 6% for the six months ended August 31, 2025, primarily due to changes in customer ordering patterns and moderation in demand.
• Operating expenses surged by 271% for the three months and 191% for the six months ended August 31, 2025, impacting overall profitability despite revenue growth.
• Cash and cash equivalents decreased by $521,591 for the six months ended August 31, 2025, indicating a net decrease in liquidity.
• The Inside the United States segment remains loss-making and is in an active build-up phase, incurring higher operating and running costs.
• The company's disclosure controls and procedures were concluded to be not effective as of August 31, 2025, raising concerns about financial reporting integrity.
• A full impairment of the note receivable from Innovative Outcomes was warranted due to financial deterioration, strategic misalignment, and lack of information, with Innovative Outcomes defaulting on the note in September 2024.

Risks

• **Revenue Concentration Risk**: 93% of total revenue for the three and six months ended August 31, 2025, was derived from a single customer, DISA Life Sciences, in South Africa, making the company highly dependent on this relationship.
• **U.S. Tariff Risk**: A newly imposed 30% U.S. tariff on all goods imported from South Africa, effective August 1, 2025, is expected to increase cost of goods sold by 30% on approximately 5% of revenue from the Domestic Sales segment, potentially reducing fiscal year gross margin by 1 to 2 percentage points.
• **Operational Challenges**: Dependence on product development, supply chain continuity, competitive positioning, industry consolidation, pricing pressures, IT disruptions, and foreign exchange volatility.
• **Financial Risks**: Substantial debt, potential need for additional financing, and exposure to interest rate changes, accounting rule shifts, and tax regulation updates.
• **Management and Governance Risks**: Reliance on a small number of key personnel (many outside the U.S.), concentrated voting power among founders, and limited public-company experience.
• **Regulatory and Legal Risks**: Delays in obtaining regulatory approvals, potential product liability, compliance with marketing and reimbursement rules, IP protection, and evolving environmental and data privacy laws.
• **Geopolitical and Regional Risks**: Political and economic instability in South Africa (e.g., load-shedding, exchange controls, FATF grey-listing), and broader geopolitical tensions and trade disputes.
• **Market and Securities Risks**: Shares trade on the OTCQX market (penny stocks), limiting liquidity; future equity issuances could dilute existing shareholders; share prices may fluctuate significantly.
• **Internal Control Weaknesses**: Disclosure controls and procedures were not effective as of August 31, 2025, indicating a risk to the reliability of financial reporting.
• **Foreign Currency Fluctuations**: Exposure to ZAR/USD exchange rate volatility, which can materially affect reported results if the Rand weakens.

Future Outlook

Management anticipates the U.S. market launch of the OutFlo Aortic Valve Dilatation Balloon Catheter in Q4 of the 2026 financial year. The company plans to undertake clinical write-ups in new territories to facilitate market entry and compliance, with an anticipated cost not exceeding $50,000. Remediation of disclosure control deficiencies is expected to be completed by the end of fiscal year 2026. The company may consider additional debt or equity financing or lines of credit to supplement cash flows from operations.

Management Comments

• "The U.S. tariff could increase cost of goods sold by 30% on approximately 5% of revenue from our Domestic Sales segment (Inside the United States), potentially reducing fiscal year gross margin by 1 to 2 percentage points if unmitigated."
• "Management anticipates that OutFlo will be launched to the U.S. Market in Q4 of the 2026 financial year, while the product is already in market in South Africa."
• "The Group now plans to replicate this proven model in the U.S. market, leveraging the FDA clearance of the Trachealator and OutFlo and the strength of our established sales force."
• "The loss-making nature of the Inside the United States segment, in contrast to the profitability of the segment outside the United States, can be attributed to the differing phases of business maturity."
• "The Company believes its current liquidity position is sufficient to meet its operating requirements for at least the next 12 months."
• "Our R&D efforts are primarily directed towards process improvements and manufacturing efficiencies rather than more speculative, high-risk developments."
• "The repayment of the related party loan is indicative of our improved financial stability and a commitment to reducing leverage, which represents a positive development for the business."

Industry Context

The global medical device market is projected to grow at a CAGR of 5.6% from 2024 to 2029, driven by rising healthcare expenditures, demographic shifts, and increasing demand in emerging markets. The U.S. medical device market is expected to grow at a CAGR of 4.3% from 2024 to 2029, fueled by advances in minimally invasive technologies and rising health spending. Medinotec's strategy to expand its footprint in these growing markets with proprietary products like Trachealator and OutFlo aligns with these trends, particularly in the demand for advanced minimal invasive medical devices. However, the company's heavy reliance on a single distributor in South Africa and the new U.S. tariff introduce significant market-specific challenges.

Comparison to Industry Standards

• The company's gross margin improvement to 62% (Q2 2025) and 55% (6 months 2025) is strong, especially compared to the prior year, but the new 30% U.S. tariff could compress future gross margins by 1-2 percentage points, potentially bringing them closer to or below industry averages for similar medical device distributors/manufacturers if unmitigated.
• The company's 'R&D-light' approach, focusing on process improvements and commercially viable projects, contrasts with some industry players that invest heavily in high-risk, long-term speculative R&D. This strategy aims for higher ROI but might limit breakthrough innovations compared to larger, more diversified medical tech firms.
• The reliance on a single customer for 93% of revenue is significantly higher than typical industry diversification standards, where companies usually aim to limit exposure to any single customer to below 10-20% to mitigate concentration risk.
• The ineffectiveness of disclosure controls and procedures is a significant governance issue that falls below industry best practices for publicly traded companies, which prioritize robust internal controls for financial reporting reliability.

Corporate Governance

Legal Proceedings

• The company is not a party to any material pending legal proceedings and is not aware of any pending legal proceeding to which its officers, directors, or 5% beneficial holders are adverse or have a material interest adverse to the company.

Related Party Transactions

• An unsecured loan payable of $160 from Minoan Medical Proprietary Limited, the prior parent entity of DISA Medinotec, controlled by CEO Dr. Gregory Vizirgianakis. This loan was significantly repaid during the period.
• An unsecured, interest-free loan payable of $283 from Minoan Capital Proprietary Limited, also controlled by CEO Dr. Gregory Vizirgianakis.
• DISA Medinotec Proprietary Limited leases commercial buildings from Minoan Capital, a related party due to mutual directorship with a Board member. Lease terms are believed to be market-related.
• Executive time from the company's distributor (where executives are permanently employed) is allocated to the company, resulting in a monthly charge of $50,000 since March 2025, recovered through product pricing.

Stakeholder Impact

• **Shareholders**: Potential for dilution if future equity financing is pursued. Share price could be negatively impacted by the U.S. tariff, customer concentration risk, and internal control deficiencies. Positive impact from strong revenue growth and debt reduction.
• **Employees**: The strategy of leveraging less expensive talent abroad for the Outside U.S. segment may impact hiring in the U.S. segment. Flat organizational structure allows for flexibility in staff roles.
• **Customers**: U.S. customers may face increased product costs due to the 30% tariff on South African imports. The heavy reliance on DISA Life Sciences in South Africa means any disruption to that relationship could impact product availability and pricing for their end-customers.
• **Suppliers**: Improved cash management and timing of payments to vendors, as indicated by the smaller increase in accounts payable, suggests stable relationships.
• **Creditors**: Significant repayment of related party debt improves the company's leverage and financial stability, which is positive for creditors.

Next Steps

• Launch OutFlo Aortic Valve Dilatation Balloon Catheter to the U.S. market in Q4 of the 2026 financial year.
• Complete remediation of disclosure control deficiencies by the end of fiscal year 2026.
• Continue assessing the impact of the U.S. tariff and evaluating contingency strategies, including sourcing alternatives, pricing adjustments, and geographic diversification.
• Pursue FDA clearance for the full range of Cape Cross PTCA catheters, with expected submission in February 2025.
• Undertake clinical write-ups in new territories to facilitate market entry and compliance with local regulations.
• Actively pursue opportunities to enhance sales and distribution operations in the U.S. to diversify revenue streams.

Key Dates

Recommendation

While Medinotec Inc. demonstrates impressive revenue growth and improved gross margins, driven by its international distribution segment, the significant risks warrant a 'hold' recommendation. The 93% revenue concentration from a single customer, the newly imposed 30% U.S. tariff, and the acknowledged ineffectiveness of disclosure controls introduce substantial uncertainty and potential downside. The U.S. segment's declining revenue and loss-making status, coupled with surging operating expenses, further temper the positive financial performance. Investors should monitor the company's progress in mitigating these risks, particularly the tariff impact and internal control remediation, before considering a stronger position.

Keywords

Medical Devices, SEC Filing, 10-Q, Medinotec, MDNC, Trachealator, OutFlo, Aortic Valve Dilatation, Coronary Catheter, South Africa, U.S. Market, FDA Clearance, Revenue Growth, Financial Results, Customer Concentration, U.S. Tariff, Disclosure Controls, Medical Technology, Healthcare